Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with T2DM diagnosed for at least 12 months and treated with insulin glargine and Humalog®/Liprolog® or NovoLog®/NovoRapid® (at least 3 times daily, before each meal) in the 6 months prior to the screening visit.~* Signed written informed consent.~Exclusion criteria:~* At screening visit, age under legal age of adulthood.~* HbA1c \<6.5% or \>10.0% at screening.~* Diabetes other than T2DM.~* Pregnancy and lactation.~* Women of childbearing potential not protected by highly effective contraceptive method of birth control.~* Use of insulin pump in the 6 months before screening visit.~* Use of insulin other than insulin glargine and Humalog or NovoLog/NovoRapid in the 6 months prior to screening visit. Liprolog® is an European Union (EU) approved insulin lispro and is allowed in those countries where it is marketed.~* Use of Humalog/Liprolog or Novolog/NovoRapid less than 3 times daily, before each meal.~* Use of non-injectable peptides (eg, Glucagon-like peptide-1 (GLP-1) receptor-agonists or other peptides) in the 6 months prior to screening visit.~* Body mass index (BMI) \>=40kg/m² at screening visit.~* Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period.~* The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR342434 (Type: EXPERIMENTAL): SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
- Humalog (Type: ACTIVE_COMPARATOR): Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).